Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years

• Verfasst von: Genadieva-Stavrik, Sonja [VerfasserIn]
• Verfasst von: Boumendil, A. [VerfasserIn]
• Verfasst von: Dreger, Peter [VerfasserIn]
• Verfasst von: Peggs, K. [VerfasserIn]
• Verfasst von: Briones, J. [VerfasserIn]
• Verfasst von: Corradini, P. [VerfasserIn]
• Verfasst von: Bacigalupo, A. [VerfasserIn]
• Verfasst von: Socié, G. [VerfasserIn]
• Verfasst von: Bonifazi, F. [VerfasserIn]
• Verfasst von: Finel, H. [VerfasserIn]
• Verfasst von: Velardi, A. [VerfasserIn]
• Verfasst von: Potter, M. [VerfasserIn]
• Verfasst von: Bruno, B. [VerfasserIn]
• Verfasst von: Castagna, L. [VerfasserIn]
• Verfasst von: Malladi, R. [VerfasserIn]
• Verfasst von: Russell, N. [VerfasserIn]
• Verfasst von: Sureda, A. [VerfasserIn]
• Titel: Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years
• Titelzusatz: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
• Verf.angabe: S. Genadieva-Stavrik, A. Boumendil, P. Dreger, K. Peggs, J. Briones, P. Corradini, A. Bacigalupo, G. Socié, F. Bonifazi, H. Finel, A. Velardi, M. Potter, B. Bruno, L. Castagna, R. Malladi, N. Russell and A. Sureda
• E-Jahr: 2016
• Jahr: 29 August 2016
• Umfang: 7 S.
• Fussnoten: Gesehen am 02.06.2020
• Titel Quelle: Enthalten in: Annals of oncology
• Ort Quelle: Amsterdam [u.a. : Elsevier, 1990
• Jahr Quelle: 2016
• Band/Heft Quelle: 27(2016), 12, Seite 2251-2257
• ISSN Quelle: 1569-8041
• DOI: doi:10.1093/annonc/mdw421
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Adult
• Sach-SW: Aged
• Sach-SW: allogeneic stem cell transplantation
• Sach-SW: Bone Marrow
• Sach-SW: conditioning regimen
• Sach-SW: Disease-Free Survival
• Sach-SW: Female
• Sach-SW: Graft vs Host Disease
• Sach-SW: Hodgkin Disease
• Sach-SW: Humans
• Sach-SW: Male
• Sach-SW: Neoplasm Recurrence, Local
• Sach-SW: relapsed/refractory Hodgkin's lymphoma
• Sach-SW: Retrospective Studies
• Sach-SW: Stem Cell Transplantation
• Sach-SW: Transplantation Conditioning
• Sach-SW: Transplantation, Homologous
• Sach-SW: Treatment Outcome
• K10plus-PPN: 1699206740

Abstract

BACKGROUND: To evaluate long-term outcome of myeloablative allogeneic stem cell transplantation (allo-SCT) (MAC) versus reduced-intensity allo-SCT (RIC) in patients with relapsed/refractory Hodgkin's lymphoma (HL) in recent years. - PATIENTS AND METHODS: A total of 312 patients (63 MAC and 249 RIC) with relapsed/refractory HL who received allo-SCT between 2006 and 2010 and were reported to the EBMT Database were included in the study. - RESULTS: With a median follow-up for alive patients of 56 (26-73) months, there were no significant differences in non-relapse mortality (NRM) between MAC and RIC. Relapse rate (RR) was somewhat lower in the MAC group (41% versus 52% at 24 months, P = 0.16). This lower RR translated into a marginal improvement in event-free survival (EFS) for the MAC group (48% versus 36% at 24 months, P = 0.09) with no significant differences in overall survival (73% for MAC and 62% for RIC at 24 months, P = 0.13). Multivariate analysis after adjusting for disease status at the time of allo-SCT showed that the use of MAC was of borderline statistical significance for predicting a lower RR and EFS [HR 0.7, 95% CI (0.5-1.0), P = 0.1] and [HR 0.7, 95% CI (0.5-1.0), P = 0.07], respectively, after allo-SCT. - CONCLUSIONS: With modern transplant practices, the NRM associated with MAC for HL has strongly decreased, resulting into non-significant improvement of EFS because of a somewhat better disease control compared with RIC transplants. The intensity of conditioning regimens should be considered when designing individual allo-SCT strategies or clinical trials in patients with relapsed/refractory HL.